Browsing: Feature Stories

One company’s approach to breaking barriers within the TME to overcome recalcitrant cancers. Earlier this month, a preview of patient-derived…

Cala Heath, Inc. is a bioelectronic medicine company that develops non-invasive neuromodulation therapies for chronic diseases through wearable devices. Their…

Prostate cancer is the second most common form of cancer affecting men in the United States – 1 in 8 men will…

Currently, even with more than 3.8 million breast cancer survivors in the United States, the disease is still the second-leading cause…

Hope for Patients Diagnosed with Rare, Aggressive Desmoid Fibromatosis Last month, SpringWorks Therapeutics announced their promising data from the Phase…

More than half of the world population lacked access to essential health services even before the COVID-19 pandemic. People living…

June is recognized as World Infertility Awareness Month. As many as 48.5 million couples experience some form of infertility due…

Intra-Cellular Therapies ended the year 2021 with a big achievement. On December 20, 2021, Dr. Sharon Mates, Chairman, and CEO…

According to the American Academy of Dermatology Association, one in five Americans will develop skin cancer in their lifetime. Skin…

LambdaVision is a biotech company, that is designing and developing a protein-based artificial retina. This retina will utilize a light-activated protein, bacteriorhodopsin to restore function sight to those who are blind due to retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP).